Complement 3 Glomerulopathy C3g Epidemiology Forecast

DelveInsight’s ‘Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Complement 3 Glomerulopathy (C3G) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Complement 3 Glomerulopathy (C3G) Understanding

The term complement 3 glomerulopathy (C3G) was adopted by expert consensus in 2013 to define a group of rare kidneys diseases driven by dysregulation of the complement cascade. The major features of C3G include high levels of protein in the urine (proteinuria), blood in the urine (hematuria), reduced amounts of urine, low levels of protein in the blood, and swelling in several areas of the body.


C3G is a type of glomerular disease, characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a significant amount of immunoglobulin and without deposition of C1q and C4. The accumulation of C3 without a significant amount of classical or lectin complement component in the glomeruli suggests dysregulation of the alternative complement pathway as the underlying pathogenetic mechanism. This finding, in the absence or near absence of immunoglobulin deposits in a patient with the classic clinical features of glomerulonephritis, is the single diagnostic criterion. The rarity of C3G makes it challenging to derive precise incidence and prevalence of the indication; however, several small cohort studies have generated estimates of limited reliability.


The term C3G includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), which are the two patterns of damage and inflammation in the glomeruli. In other words, the damage and inflammation in the kidney tissue in DDD appear different from that in C3GN when observed under a microscope. People with DDD generally present at a younger age (childhood or adolescence) compared to people with C3GN (adulthood).


The classification and nomenclature of this indication have drastically evolved over the years. Therefore, it is crucial to know the history of the naming system for C3G because some patients who were diagnosed with the disease before the new classification proposed in 2013 were introduced to know their disease by a different name. Before 2013, a portion of C3G patients carried the diagnosis of “membranoproliferative glomerulonephritis (MPGN)” or “mesangio proliferative glomerulonephritis.” These same patients are now referred to as C3G patients based on the microscopic appearance of their glomeruli and the new definition of the disease.


Dysregulation of the complement alternative pathway, driven by acquired and/or genetic defects, plays a pathogenetic role in C3G. The most common acquired drivers of C3G are the C3 nephritic factors (C3NeFs), heterogeneous autoantibodies that stabilize the C3 convertase, C3bBb. Although present in many different disease conditions and reported in normal individuals, most DDD patients (80–85%) and many C3GN patients (∼50%) develop these autoantibodies, which prolong convertase half-life and promote fluid-phase AP dysregulation. In both DDD and C3GN, the profile of serological complement biomarkers is consistent with over-activity of the AP and terminal pathway (TP).


Complement 3 Glomerulopathy (C3G) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G), Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G) and Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Complement 3 Glomerulopathy (C3G) Detailed Epidemiology Segmentation

  • The total diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) in the seven major markets was found to be 8,175 in 2017.
  • The diagnosed prevalent cases of Complement 3 Glomerulopathy (C3G), in the United States, were found to be 3,967 in 2017.
  • It was found that in the United States, the number of cases of DDD and C3GN was 1,349 and 2,619, respectively, in 2017.
  • Age-specific data for C3G suggests that in the United States the highest and the lowest number of cases of DDD were found in the age group of 18–50 with 830 cases and age-group >50 with 243 cases, respectively, in 2017, while the highest and the lowest number of cases of C3GN were found in the age group of 18–50 with 1,705 cases and age-group <18 with 440 cases, respectively, in 2017.
  • In the EU5 countries, the diagnosed prevalence of Complement 3 Glomerulopathy (C3G) was found to be maximum in Germany with 820 cases, followed by the France with 685 cases in 2017. While, the least number of cases were found in Spain, with 496 cases in 2017.
  • In Japan, the diagnosed prevalence of Complement 3 Glomerulopathy (C3G) was found to be 912 in 2017.

Scope of the Report

  • The report covers the descriptive overview of Complement 3 Glomerulopathy (C3G), explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Complement 3 Glomerulopathy (C3G).
  • The report provides the segmentation of the disease epidemiology for the 7MM by Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G) and Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G).

Report Highlights

  • Eleven Year Forecast of Complement 3 Glomerulopathy (C3G)
  • 7MM Coverage
  • Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G)
  • As per DelveInsight’s analysis, Complement 3 Glomerulopathy (C3G) can be divided into two types, namely, Dense Deposit Disease (DDD) and C3 glomerulonephritis (C3GN).
  • The report also encompasses another major segment, i.e., Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G), wherein various age groups have been considered, such as <18, 18–50 and >50. It has been found that the diagnosed prevalence of both DDD and C3GN has been found maximum in the 18–50 age group.
  • Expected Launch of potential therapies, Danicopan (Alexion Pharmaceuticals), Narsoplimab (Omeros Corporation), Pegcetacoplan (Apellis Pharmaceuticals) and LNP023 (Novartis Pharmaceuticals), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Complement 3 Glomerulopathy (C3G).
  • The current treatment of Complement 3 Glomerulopathy (C3G) is mainly dominated by the use of off-label therapies, which includes Immunosuppressant, Steroids, Renin–angiotensin–aldosterone system Inhibitors (RAAS) and Other Supportive Therapies (also including Antibody regimens: Eculizumab and Rituximab).

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Complement 3 Glomerulopathy (C3G)?
  • What is the historical Complement 3 Glomerulopathy (C3G) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Complement 3 Glomerulopathy (C3G) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Complement 3 Glomerulopathy (C3G)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Complement 3 Glomerulopathy (C3G) during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy

The Complement 3 Glomerulopathy (C3G) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Complement 3 Glomerulopathy (C3G) market.
  • Quantify patient share distribution in the 7MM for Complement 3 Glomerulopathy (C3G).
  • The Complement 3 Glomerulopathy (C3G) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Complement 3 Glomerulopathy (C3G) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

1 Key Insights

2 C3G Overview at a Glance

3 Executive Summary of Complement 3 Glomerulopathy (C3G)

4 Complement 3 Glomerulopathy (C3G): Disease Background and Overview

4.1 Types

4.1.1 Dense Deposit Disease (DDD)

4.1.2 C3 glomerulonephritis (C3GN)

4.2 Familiar forms of C3G

4.2.1 CFHR5 nephropathy

4.2.2 Other familiar forms of C3G

4.3 Causes and Risk Factors

4.3.1 Genetic or Hereditary Risk Factors

4.3.2 Acquired Risk Factors

4.4 Clinical Presentation

4.5 Histological Patterns

4.6 Symptoms

4.7 Pathophysiology

4.8 Pathogenesis

4.9 Diagnosis

4.10 Challenges in Diagnosis

4.10.1 Immune complex glomerulonephritis

4.10.2 Postinfectious glomerulonephritis

4.10.3 Predictors of progression

4.11 Differential Diagnosis

4.12 Prognosis

5 Algorithm for diagnosis and management of C3G

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy

7 Country Wise-Epidemiology of Complement 3 Glomerulopathy

7.1 United States

7.1.1 Assumptions and Rationale

7.1.2 Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy in the US

7.1.3 Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in the US

7.1.4 Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in the US

7.2 EU5 Countries

7.2.1 Assumptions and Rationale

7.3 Germany

7.3.1 Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy in Germany

7.3.2 Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in Germany

7.3.3 Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in Germany

7.4 France

7.4.1 Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy in France

7.4.2 Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in France

7.4.3 Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in France

7.5 Italy

7.5.1 Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy in Italy

7.5.2 Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in Italy

7.5.3 Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in Italy

7.6 Spain

7.6.1 Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy in Spain

7.6.2 Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in Spain

7.6.3 Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in Spain

7.7 United Kingdom

7.7.1 Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy in the UK

7.7.2 Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in the UK

7.7.3 Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in the UK

7.8 Japan

7.8.1 Assumptions and Rationale

7.8.2 Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy in Japan

7.8.3 Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in Japan

7.8.4 Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in Japan

8 Appendix

8.1 Bibliography

8.2 Report Methodology

9 DelveInsight Capabilities

10 Disclaimer

11 About DelveInsight

List of Tables

 Table 1: Summary of Complement 3 Glomerulopathy (C3G), Epidemiology and Key Events (2017–2030)

Table 2: Factor-H-related fusion proteins in familial C3G

Table 3: Acquired drivers of C3G

Table 4: Diagnostic procedure for patients suspected of C3G

Table 5: Total Diagnosed Prevalent Population of C3G in the 7MM (2017–2030)

Table 6: Total Diagnosed Prevalent Population of C3G in the United States (2017–2030)

Table 7: Type-specific Diagnosed Prevalent Population of C3G in the United States (2017–2030)

Table 8: Age-specific Diagnosed Prevalent Population of C3G in the United States (2017–2030)

Table 9: Total Diagnosed Prevalent Population of C3G in Germany (2017–2030)

Table 10: Type-specific Diagnosed Prevalent Population of C3G in Germany (2017–2030)

Table 11: Age-specific Diagnosed Prevalent Population of C3G in Germany (2017–2030)

Table 12: Total Diagnosed Prevalent Population of C3G in France (2017–2030)

Table 13: Type-specific Diagnosed Prevalent Population of C3G in France (2017–2030)

Table 14: Age-specific Diagnosed Prevalent Population of C3G in France (2017–2030)

Table 15: Total Diagnosed Prevalent Population of C3G in Italy (2017–2030)

Table 16: Type-specific Diagnosed Prevalent Population of C3G in Italy (2017–2030)

Table 17: Age-specific Diagnosed Prevalent Population of C3G in Italy (2017–2030)

Table 18: Total Diagnosed Prevalent Population of C3G in Spain (2017–2030)

Table 19: Type-specific Diagnosed Prevalent Population of C3G in Spain (2017–2030)

Table 20: Age-specific Diagnosed Prevalent Population of C3G in Spain (2017–2030)

Table 21: Total Diagnosed Prevalent Population of C3G in the United Kingdom (2017–2030)

Table 22: Type-specific Diagnosed Prevalent Population of C3G in the United Kingdom (2017–2030)

Table 23: Age-specific Diagnosed Prevalent Population of C3G in the United Kingdom (2017–2030)

Table 24: Total Diagnosed Prevalent Population of C3G in Japan (2017–2030)

Table 25: Type-specific Diagnosed Prevalent Population of C3G in Japan (2017–2030)

Table 26: Age-specific Diagnosed Prevalent Population of C3G in Japan (2017–2030)

List of Figures

 Figure 1: Key causes and risk factors of C3G

Figure 2: Signs and symptoms of C3G

Figure 3: C3-dominant glomerulonephritis disease classification

Figure 4: Complement system pathways

Figure 5: Schematic dysregulation of the C3 activation in C3G

Figure 6: Algorithm for diagnosis and management of C3G

Figure 7: Total Diagnosed Prevalent Population of C3G in the 7MM (2017–2030)

Figure 8: Total Diagnosed Prevalent Population of C3G in the United States (2017–2030)

Figure 9: Type-specific Diagnosed Prevalent Population of C3G in the United States (2017–2030)

Figure 10: Age-specific Diagnosed Prevalent Population of DDD in the United States (2017–2030)

Figure 11: Age-specific Diagnosed Prevalent Population of C3GN in the United States (2017–2030)

Figure 12: Total Diagnosed Prevalent Population of C3G in Germany (2017–2030)

Figure 13: Type-specific Diagnosed Prevalent Population of C3G in Germany (2017–2030)

Figure 14: Age-specific Diagnosed Prevalent Population of DDD in Germany (2017–2030)

Figure 15: Age-specific Diagnosed Prevalent Population of C3GN in Germany (2017–2030)

Figure 16: Total Diagnosed Prevalent Population of C3G in France (2017–2030)

Figure 17: Type-specific Diagnosed Prevalent Population of C3G in France (2017–2030)

Figure 18: Age-specific Diagnosed Prevalent Population of DDD in France (2017–2030)

Figure 19: Age-specific Diagnosed Prevalent Population of C3GN in France (2017–2030)

Figure 20: Total Diagnosed Prevalent Population of C3G in Italy (2017–2030)

Figure 21: Type-specific Diagnosed Prevalent Population of C3G in Italy (2017–2030)

Figure 22: Age-specific Diagnosed Prevalent Population of DDD in Italy (2017–2030)

Figure 23: Age-specific Diagnosed Prevalent Population of C3GN in Italy (2017–2030)

Figure 24: Total Diagnosed Prevalent Population of C3G in Spain (2017–2030)

Figure 25: Type-specific Diagnosed Prevalent Population of C3G in Spain (2017–2030)

Figure 26: Age-specific Diagnosed Prevalent Population of DDD in Spain (2017–2030)

Figure 27: Age-specific Diagnosed Prevalent Population of C3GN in Spain (2017–2030)

Figure 28: Total Diagnosed Prevalent Population of C3G in the United Kingdom (2017–2030)

Figure 29: Type-specific Diagnosed Prevalent Population of C3G in the United Kingdom (2017–2030)

Figure 30: Age-specific Diagnosed Prevalent Population of DDD in the United Kingdom (2017–2030)

Figure 31: Age-specific Diagnosed Prevalent Population of C3GN in the United Kingdom (2017–2030)

Figure 32: Total Diagnosed Prevalent Population of C3G in Japan (2017–2030)

Figure 33: Type-specific Diagnosed Prevalent Population of C3G in Japan (2017–2030)

Figure 34: Age-specific Diagnosed Prevalent Population of DDD in Japan (2017–2030)

Figure 35: Age-specific Diagnosed Prevalent Population of C3GN in Japan (2017–2030)

  • Tags:
  • Complement 3 Glomerulopathy (C3G) E...
  • Complement 3 Glomerulopathy (C3G)
  • Complement 3 Glomerulopathy (C3G)...
  • Complement 3 Glomerulopathy (C3G)...
  • Complement 3 Glomerulopathy (C3G)...

Forward to Friend

Need A Quote